STOCK TITAN

Icad Inc - ICAD STOCK NEWS

Welcome to our dedicated news page for Icad (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icad's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icad's position in the market.

Rhea-AI Summary
iCAD, Inc. announces partnership with Densitas and showcases ProFound Cloud at SBI symposium, highlighting advancements in breast cancer detection technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
partnership
-
Rhea-AI Summary
iCAD partners with Densitas to offer a comprehensive breast health solution, integrating AI-powered solutions for breast cancer screening, detection, density assessment, and risk evaluation. The collaboration aims to enhance early cancer detection and intervention, providing a holistic approach to precision breast health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
partnership AI
-
Rhea-AI Summary
iCAD's AI Algorithm Successfully Detects Breast Arterial Calcification, Signaling Cardiovascular Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
AI
Rhea-AI Summary
iCAD partners with RAD-AID International to implement ProFound AI Detection for improving mammography reading and breast cancer detection in low-resource institutions and medically underserved communities. The collaboration aims to enhance breast imaging accuracy and efficiency in Guyana and other LMICs, promoting early cancer detection and health equity globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
partnership AI
-
Rhea-AI Summary
iCAD, Inc. announces the commercial availability of ProFound Cloud, a Software-as-a-Service platform powered by Google Cloud and AI innovations, revolutionizing breast cancer detection. The platform provides cost-effective, secure, and scalable access to AI solutions for medical providers, enhancing patient outcomes through early cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
AI
-
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) introduces advanced features in its ProFound Detection solution for mammography, enhancing radiologists' interpretability and efficiency. The new capabilities include limiting lesion marks, color-coding lesions, and providing color-coded ProFound Scorecards. These features aim to streamline the diagnostic process, improve readability, and aid in accurate cancer detection, showcasing iCAD's commitment to advancing cancer detection technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) reports annual recurring revenue of $8.7 million, a 15% increase year-over-year. Full-year operating cash flow improved to ($5) million from ($12.8) million. Despite a 13% decrease in total revenues for 2023, the company saw a rise in gross profit margin to 91% in Q4 2023. The GAAP net loss from continuing operations improved to ($0.5) million in Q4 2023. iCAD's President and CEO, Dana Brown, highlighted strong execution and progress towards the company's transformation plan. iCAD remains optimistic about its cash resources and future operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
-
Rhea-AI Summary
iCAD, Inc. highlights clinical evidence showing its AI solutions can reduce breast interval cancer rates and recall rates while lowering radiology reading workload. The company's ProFound Detection solution may serve as a biomarker for evaluating cardiovascular disease. New research presented at ECR 2024 demonstrates the efficacy of iCAD's AI in improving mammography screening efficiency and accuracy. The company also introduces enhancements to its ProFound Detection solution and showcases its Breast Health Suite at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
-
Rhea-AI Summary
iCAD, Inc. (ICAD) appoints renowned radiologist Dr. Hricak to its Board of Directors. Dr. Hricak brings over 40 years of experience in radiology and research, focusing on developing new diagnostic imaging techniques for genitourinary cancers. Her global health initiatives aim to improve access to oncologic imaging and cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
management
Rhea-AI Summary
iCAD, Inc. to Release Q4 and Full Year 2023 Financial Results; Hosts Earnings Call on March 12, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences earnings
Icad Inc

Nasdaq:ICAD

ICAD Rankings

ICAD Stock Data

44.80M
24.81M
5.86%
30.97%
1.57%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States
Nashua

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.